Last reviewed · How we verify
NCT05279638
ATG5 as a Serum Marker of Autophagy in Psoriatic Patient
trial testing serum ATG5 in Psoriasis Vulgaris in 90 participants. Status unknown.
1 February 2023
Quick facts
| Lead sponsor | Sohag University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 1 February 2022 |
| Primary completion | 1 February 2023 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- serum ATG5
Conditions studied
- Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →
- Autophagy — all drugs for Autophagy →
Sponsor
Sohag University
Who can join
Adults 18 to 55, any sex, with Psoriasis Vulgaris or Autophagy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Autophagy and mitophagy in dermatological disease: a comprehensive review from molecular pathways to therapeutic frontiers.
D'Ambrosio L, Greco ME, Forte M, Vecchio D, et al · · 2025 · cited 1× · PMID 41353197 · DOI 10.1186/s13062-025-00703-1
Verify or expand the search:
- PubMed search for NCT05279638
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psoriasis Vulgaris
Currently open trials in the same condition.
- NCT07426120 — Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III · Phase 3 · recruiting
- NCT07320872 — Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris · recruiting
- NCT06398106 — Proactive TDM Versus Standard Use of Biologics in Psoriasis · Phase 4 · recruiting
- NCT05185258 — Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study · Phase 4 · active not recruiting
- NCT04950218 — Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis · recruiting
Other Sohag University trials
Trials by the same sponsor.
- NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
- NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
- NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
- NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05279638 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sohag University
- Last refreshed: 15 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05279638.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing